ELV

### Comprehensive Stock Analysis: Elevance Health Inc (ELV)  
**Ticker:** ELV | **Sector:** Healthcare | **Market Cap:** $76.61B | **Price:** $340.24 | **Next Earnings Date:** July 17, 2025  

---

#### **1. Valuation Analysis: Overvalued Relative to Growth Prospects**  
Elevance Health trades at a **trailing P/E of 14.48** (below S&P 500 average of ~20–25), but the **PEG ratio of 4.72** is a critical red flag.  
- **Why it matters:** A PEG >1 indicates the stock is expensive relative to its earnings growth. Here, the PEG of 4.72 suggests the market is pricing in **very modest growth** (e.g., 5-year EPS growth of 6.81%) but expects a high price.  
- **Forward P/E (10.81)** is even lower, signaling optimism about future earnings, but the **high PEG** implies this optimism is overextended.  
- **Key Insight:** While the stock is *currently undervalued* vs. the S&P 500 (P/E), the **PEG ratio** dominates the analysis. This is a classic case of "low P/E but high PEG" – the stock is expensive for its growth trajectory. **Risks:** If earnings growth fails to meet expectations (next year’s growth is only +4.57%), the stock could fall sharply.  

---

#### **2. Earnings & Revenue Trends: Short-Term Dip, Long-Term Resilience**  
- **EPS Trends:**  
  - **TTM EPS:** $23.49 (declined **-8.87%** YoY) – recent dip due to operational headwinds (e.g., rising premiums, cost pressures).  
  - **Next Year EPS Growth:** +4.57% (positive but modest) – a sign of recovery.  
  - **5-Year EPS Growth:** +6.81% (strong, but recent slowdown is concerning).  
- **Revenue Trends:**  
  - **YoY Revenue Growth (TTM):** +10.21% – robust expansion driven by healthcare plan uptake.  
  - **5-Year Revenue Growth:** +11.15% – consistent growth in the insurance sector.  
- **Key Insight:** The company has **recovered from a recent earnings slump** (EPS down 8.87% this year) but growth is slowing. The positive next-year EPS forecast suggests resilience, but the *low growth rate* (4.57%) aligns with the high PEG.  

---

#### **3. Dividend Profile: Strong Growth, Low Yield**  
- **Dividend Yield:** 0.2% (very low) – **not suitable for income investors**.  
- **Dividend Growth:**  
  - **5-Year CAGR:** +15.3% (exceptional for healthcare insurance)  
  - **1-Year Growth:** +10.14% (strong momentum)  
- **Payout Ratio:** 25.39% (low) – company retains most earnings for growth (ideal for long-term investors).  
- **Key Insight:** Elevance is a **dividend growth stock** with a strong history, but the **low yield** makes it unsuitable for income-focused portfolios. The payout ratio is healthy, but the lack of dividends in the short term (due to high PEG) means the stock is more of a *growth play* than an income play.  

---

#### **4. Financial Health: Solid Margins, Manageable Debt**  
- **Profit Margins:**  
  - **Operating Margin:** 4.46% (healthy for healthcare insurance)  
  - **Net Profit Margin:** 2.83% (low but typical in insurance due to regulatory costs and claims volatility)  
- **Debt Metrics:**  
  - **Total Debt-to-Equity:** 0.69 (69%) – **manageable** (below the 1.0 threshold for high risk).  
  - **LT Debt-to-Equity:** 0.64 (64%) – no immediate debt distress.  
- **Key Insight:** The company has **strong financial discipline** (low debt, high retention of earnings) but **thin margins** – a common challenge in the healthcare insurance sector due to cost pressures and regulatory complexity.  

---

#### **5. Market Sentiment & Trading Dynamics**  
- **Short Interest:** 3.68% of float (low) – **not a major risk** (short ratio of 1.48 indicates minimal bearish pressure).  
- **Beta:** 0.6 (less volatile than the S&P 500) – ideal for risk-averse investors.  
- **Recent Performance:**  
  - **+2.28%** in last trade (positive momentum).  
  - **RSI (14-day):** 66.97 (neutral – not overbought/oversold).  
  - **52-Week Range:** $273.71–$510.24 (current price near the top end of the range).  
- **Key Insight:** The stock is **trading near its 52-week high** with strong institutional interest (92.75% ownership). This suggests **bullish sentiment** but also potential overvaluation.  

---

#### **6. Sector Context & News Impact**  
- **Healthcare Sector:** Facing rising premiums, regulatory pressures, and cost inflation. Elevance benefits from **rising premiums** (per recent news).  
- **News Alert (July 17, 2025):**  
  > *"Humana Benefits From Rising Premiums Amid High Benefit Ratio"* (note: ELV is Elevance Health, not Humana – likely a data error).  
  - **Implication:** If true, rising premiums could boost Elevance’s revenue (as seen in the 10.21% YoY growth). However, the news title’s confusion with Humana (a competitor) reduces credibility.  
- **Key Insight:** The healthcare insurance sector is **growth-oriented** but sensitive to regulatory changes. Elevance’s revenue growth aligns with sector trends, but the stock’s high PEG makes it vulnerable to any slowdown in premium growth.  

---

#### **7. Risk Assessment: What Could Break This Stock?**  
| Risk Factor | Likelihood | Impact | Mitigation |
|-------------|------------|--------|-------------|
| **Earnings miss next quarter** | Medium | High (PEG >1) | Monitor Q3 earnings |
| **Rising interest rates** | Medium | Medium (low debt) | Beta 0.6 buffers volatility |
| **Regulatory changes** | High | High (sector-specific) | Strong institutional ownership |
| **Dividend cuts** | Low | Low (payout ratio is low) | Not a concern |

**Top Risk:** The **high PEG ratio (4.72)** – if earnings growth fails to accelerate (e.g., next year’s growth is only +4.57%), the stock could drop 15–20% in a short period.  

---

#### **8. Conclusion & Strategic Recommendations**  
**Overall Rating:** ⚠️ **Caution** (High PEG, but solid fundamentals)  

- **For Growth Investors:** ELV is a **long-term play** with strong revenue growth (10.21% YoY), low debt, and a history of dividend growth. However, the **high PEG ratio** makes it expensive relative to its growth trajectory. **Target:** 10–15% annual return over 3–5 years (if earnings growth accelerates).  
- **For Income Investors:** **Avoid** – the 0.2% yield is too low, and the company’s low payout ratio means no near-term dividend growth.  
- **For Risk-Averse Investors:** The low short interest (3.68%) and beta of 0.6 make it a **low-volatility option**, but the PEG ratio suggests it’s overpriced for the current growth outlook.  

**Key Action Steps:**  
1. **Monitor Q3 2025 earnings** – if EPS growth exceeds 4.57%, the stock could rebound.  
2. **Watch for regulatory shifts** – healthcare insurance is highly sensitive to policy changes.  
3. **Avoid buying if PEG >3** – this stock is currently at 4.72 (overvalued).  

> 💡 **Final Thought:** Elevance Health is a **strong insurance company** with a history of growth, but the **high PEG ratio** signals it’s expensive for its growth story. It’s better suited for **long-term growth investors** who can tolerate short-term volatility than for income-focused or short-term traders.

---

**Disclaimer:** This analysis is based on the provided data and does not constitute financial advice. Always conduct your own research or consult a financial advisor before making investment decisions.